| Fennec Pharmaceuticals Inc.

Khalid Islam

Member of the Audit Committee

Khalid Islam

Director

Marco Brughera

Marco Brughera

Director

Chris Rallis

Chris Rallis

Director

Financial Expert

Rosty Raykov

Rosty Raykov

Director

Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

Read more about Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

ADHEREX ANNOUNCES SODIUM THIOSULFATE CLINICAL STUDY UPDATE

Read more about ADHEREX ANNOUNCES SODIUM THIOSULFATE CLINICAL STUDY UPDATE

ADHEREX PROVIDES CORPORATE UPDATE AND FISCAL YEAR ENDED DECEMBER 31, 2013 FINANCIAL RESULTS

Read more about ADHEREX PROVIDES CORPORATE UPDATE AND FISCAL YEAR ENDED DECEMBER 31, 2013 FINANCIAL RESULTS

ADHEREX ANNOUNCES TWO SODIUM THIOSULFATE PRESENTATIONS FOR PREVENTION OF OTOTOXICITY IN CHILDREN AT ASCO MEETING

Read more about ADHEREX ANNOUNCES TWO SODIUM THIOSULFATE PRESENTATIONS FOR PREVENTION OF OTOTOXICITY IN CHILDREN AT ASCO MEETING

ADHEREX APPOINTS TWO INDEPENDENT DIRECTORS

Read more about ADHEREX APPOINTS TWO INDEPENDENT DIRECTORS

ADHEREX PROVIDES CORPORATE UPDATE AND FIRST QUARTER ENDED MARCH 31, 2014 FINANCIAL RESULTS

Read more about ADHEREX PROVIDES CORPORATE UPDATE AND FIRST QUARTER ENDED MARCH 31, 2014 FINANCIAL RESULTS